Literature DB >> 26215454

Oleanolic acid alleviated pressure overload-induced cardiac remodeling.

Hai-Han Liao1,2, Nan Zhang3, Hong Feng4, Ning Zhang1,2, Zhen-Guo Ma1,2, Zheng Yang1,2, Yuan Yuan1,2, Zhou-Yan Bian1,2, Qi-Zhu Tang5,6.   

Abstract

Previous study has demonstrated that oleanolic acid (OA) possessing the anti-inflammatory and anti-oxidant properties blunted high-glucose-induced diabetic cardiomyopathy and ameliorated experimental autoimmune myocarditis in mice. However, little is known about its effects on pressure overload-induced cardiac remodeling. Herein, we investigated the effect of OA on cardiac remodeling and underlying mechanism. Mice, subjected to aortic banding (AB), were randomly assigned into control group and experimental group. OA premixed in diets was administered to mice after 3 days of AB. Echocardiography and catheter-based measurements of hemodynamic parameters were performed after 8 weeks' treatment of OA. Histologic examination and molecular analyses were used to assess cardiac hypertrophy and tissue fibrosis. In addition, the inhibitory effects of OA on H9c2 cardiomyocytes and cardiac primary fibroblast responded to the stimulation of AngII were also investigated. OA ameliorated the systolic and diastolic dysfunction induced by pressure overload evidenced by echocardiography and catheter-based measurements. OA also decreased the mRNA expression of cardiac hypertrophy and fibrosis markers evidenced by RT-PCR. It has been shown in our study that pressure overload activated the phosphorylations of Akt, mTOR, p70s6k, S6, GSK3β, and FoxO3a, and treatment of OA attenuated the phosphorylation of these proteins. In addition, hypertrophy of cardiomyocytes and fibrosis markers induced by AngII was inhibited by OA in vitro. Our findings uncover that OA suppressed AB-induced cardiac hypertrophy, partly by inhibiting the activity of Akt/mTOR pathway, and suggest that treatment of OA may have a benefit on retarding the progress of cardiac remodeling under long terms of pressure overload.

Entities:  

Keywords:  Akt/mTOR; Cardiac hypertrophy; Fibrosis; Oleanolic acid

Mesh:

Substances:

Year:  2015        PMID: 26215454     DOI: 10.1007/s11010-015-2520-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

1.  Oleanolic acid prevents glucocorticoid-induced hypertension in rats.

Authors:  Sagar S Bachhav; Savita D Patil; Mukesh S Bhutada; Sanjay J Surana
Journal:  Phytother Res       Date:  2011-02-24       Impact factor: 5.878

2.  Indole-3-carbinol protects against pressure overload induced cardiac remodeling via activating AMPK-α.

Authors:  Wei Deng; Jing Zong; Zhouyan Bian; Heng Zhou; Yuan Yuan; Rui Zhang; Haipeng Guo; Yan Zhang; Difei Shen; Hongliang Li; Qizhu Tang
Journal:  Mol Nutr Food Res       Date:  2013-04-27       Impact factor: 5.914

Review 3.  ECM remodeling in hypertensive heart disease.

Authors:  Bradford C Berk; Keigi Fujiwara; Stephanie Lehoux
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 4.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

Review 5.  Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Authors:  Karen T Liby; Michael B Sporn
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

6.  The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

Authors:  David P Nichols; Assem G Ziady; Samuel L Shank; Jean F Eastman; Pamela B Davis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-21       Impact factor: 5.464

7.  Triterpenoid saponin, oleanolic acid 3-O-beta-d-glucopyranosyl(1-->3)-alpha-l-rhamnopyranosyl(1-->2)-alpha-l-arabinopyranoside (OA) from Aralia elata inhibits LPS-induced nitric oxide production by down-regulated NF-kappaB in raw 264.7 cells.

Authors:  Seok-Jong Suh; Un-Ho Jin; Kyung-Woon Kim; Jong-Keun Son; Seung Ho Lee; Kun-Ho Son; Hyen Wook Chang; Young-Choon Lee; Cheorl-Ho Kim
Journal:  Arch Biochem Biophys       Date:  2007-09-04       Impact factor: 4.013

Review 8.  Targeting cardiac hypertrophy: toward a causal heart failure therapy.

Authors:  Egbert Bisping; Paulina Wakula; Michael Poteser; Frank R Heinzel
Journal:  J Cardiovasc Pharmacol       Date:  2014-10       Impact factor: 3.105

Review 9.  Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy.

Authors:  Risto Kerkelä; Kathleen Woulfe; Thomas Force
Journal:  Trends Cardiovasc Med       Date:  2007-04       Impact factor: 6.677

10.  Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction.

Authors:  Rudo F Mapanga; Uthra Rajamani; Nonkululeko Dlamini; Makhosazane Zungu-Edmondson; Roisin Kelly-Laubscher; Mohammed Shafiullah; Athiq Wahab; Mohamed Y Hasan; Mohamed A Fahim; Philippe Rondeau; Emmanuel Bourdon; M Faadiel Essop
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more
  7 in total

1.  Apigenin alleviates STZ-induced diabetic cardiomyopathy.

Authors:  Huang-Jun Liu; Yun-Lin Fan; Hai-Han Liao; Yuan Liu; Si Chen; Zhen-Guo Ma; Ning Zhang; Zheng Yang; Wei Deng; Qi-Zhu Tang
Journal:  Mol Cell Biochem       Date:  2017-02-07       Impact factor: 3.396

2.  Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis.

Authors:  Si-Chi Xu; Zhen-Guo Ma; Wen-Ying Wei; Yu-Pei Yuan; Qi-Zhu Tang
Journal:  PPAR Res       Date:  2017-01-03       Impact factor: 4.964

3.  Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1.

Authors:  Hai-Han Liao; Jin-Xiu Zhu; Hong Feng; Jian Ni; Nan Zhang; Si Chen; Huang-Jun Liu; Zheng Yang; Wei Deng; Qi-Zhu Tang
Journal:  Oxid Med Cell Longev       Date:  2017-09-24       Impact factor: 6.543

4.  Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.

Authors:  Xiaotong Song; Yue Zhao; Shijun Wang; Yuan Wang; Qian Chen; Haijun Zhao; Hua Wang; Sheng Tian; Huayun Yu; Zhichun Wu
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

5.  Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation.

Authors:  Hong Feng; Shan-Qi Mou; Wen-Jing Li; Nan Zhang; Zi-Ying Zhou; Wen Ding; Zhou-Yan Bian; Hai-Han Liao
Journal:  Oxid Med Cell Longev       Date:  2020-08-25       Impact factor: 6.543

6.  Gut Microbiota and Metabolites in Atrial Fibrillation Patients and Their Changes after Catheter Ablation.

Authors:  Kang Huang; Yuegang Wang; Yang Bai; Qiuyan Luo; Xuancai Lin; Qiuyu Yang; Shihao Wang; Hongjie Xin
Journal:  Microbiol Spectr       Date:  2022-04-06

7.  Antihypertensive activity of oleanolic acid is mediated via downregulation of secretory phospholipase A2 and fatty acid synthase in spontaneously hypertensive rats.

Authors:  Shiming Zhang; Yuecheng Liu; Xiaoming Wang; Zhenhua Tian; Dongmei Qi; Yunlun Li; Haiqiang Jiang
Journal:  Int J Mol Med       Date:  2020-09-30       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.